Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells
- PMID: 15934727
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells
Abstract
A single tumor contains a heterogeneous population of cancer cells. Some cancer cells express antigens and are susceptible to specific CTLs. However, other cancer cells are antigen-loss variants (ALVs) that escape these CTLs because they express little or no antigen. Here, we show that antigen-specific T cells can eliminate ALVs when the parental population expresses a model gp33 antigen (KAVYNFATM) at a level sufficient to be locally cross-presented by the nonmalignant stromal cells. That is, the ALVs are eliminated as bystanders because the stroma is destroyed. ALVs escape bystander killing when the bone marrow-derived and/or non-bone marrow-derived stroma does not express the appropriate MHC or when the amount of antigen is too low for effective cross-presentation. The rapid destruction of the stroma, including bone marrow-derived as well as sessile components, and of the parental cancer cells, may be essential for the complete rejection of established tumors by preventing variant escape.
Similar articles
-
Bystander elimination of antigen loss variants in established tumors.Nat Med. 2004 Mar;10(3):294-8. doi: 10.1038/nm999. Epub 2004 Feb 22. Nat Med. 2004. PMID: 14981514
-
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.Clin Cancer Res. 2006 Dec 15;12(24):7422-30. doi: 10.1158/1078-0432.CCR-06-1862. Clin Cancer Res. 2006. PMID: 17189415
-
Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.Eur J Immunol. 1997 Oct;27(10):2702-7. doi: 10.1002/eji.1830271033. Eur J Immunol. 1997. PMID: 9368629
-
On cross-priming of MHC class I-specific CTL: rule or exception?Eur J Immunol. 2002 Sep;32(9):2385-92. doi: 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V. Eur J Immunol. 2002. PMID: 12207322 Review. No abstract available.
-
The role of tumor stroma in the interaction between tumor and immune system.Curr Opin Immunol. 2005 Apr;17(2):180-6. doi: 10.1016/j.coi.2005.01.008. Curr Opin Immunol. 2005. PMID: 15766679 Review.
Cited by
-
Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.Int J Cancer. 2012 Aug 15;131(4):844-54. doi: 10.1002/ijc.26447. Epub 2011 Nov 30. Int J Cancer. 2012. PMID: 21935923 Free PMC article.
-
Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.Oncol Lett. 2017 Jul;14(1):283-292. doi: 10.3892/ol.2017.6125. Epub 2017 May 5. Oncol Lett. 2017. PMID: 28693166 Free PMC article.
-
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.J Immunother Cancer. 2018 Jun 6;6(1):48. doi: 10.1186/s40425-018-0368-0. J Immunother Cancer. 2018. PMID: 29871672 Free PMC article.
-
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors.Clin Cancer Res. 2014 Feb 1;20(3):644-57. doi: 10.1158/1078-0432.CCR-13-1334. Epub 2013 Dec 3. Clin Cancer Res. 2014. PMID: 24300786 Free PMC article.
-
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases.Oncoimmunology. 2025 Dec;14(1):2514041. doi: 10.1080/2162402X.2025.2514041. Epub 2025 Jun 14. Oncoimmunology. 2025. PMID: 40515594 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials